Miramar Labs CEO Interviewed on Bloomberg Radio

Print 12 September 2016

SANTA CLARA, Calif., Sept. 12, 2016 -- Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the company’s CEO, Mike Kleine, was interviewed on Bloomberg Radio’s “Taking Stock” on September, 12th, 2016 at 3:15pm EDT.

In the interview, Mr. Kleine discussed the commercial momentum of the miraDry procedure and the significant market opportunity for the Company. The interview can be viewed at 
http://www.bloomberg.com/news/audio/2016-09-12/miramar-labs-wipes-away-sweat-glands-and-odor-audio

“This interview with Bloomberg further demonstrates there is a growing interest in our company and the miraDry procedure. This is only one of the several steps we are taking to raise awareness and tell our story to current and potential investors, customers and patients,” commented Mr. Kleine.

About Miramar Labs
Miramar Labs, Inc., is a global medical device company dedicated to bringing innovative and clinically proven applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that hundreds of millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 70,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news